Moderna计划在2027年前获得10项新批准
马萨诸塞州剑桥 - Moderna Inc. (NASDAQ: MRNA) 宣布了其战略重点，计划在未来三年内获得多达10项新产品批准。这一计划包括推动现有疫苗销售，并在2027年前将年度研发支出削减11亿美元。
安科生物涨1.67%，成交额1.21亿元，主力没有控盘
截至9月30日，安科生物股东户数6.66万，较上期减少1.49%；人均流通股18252股，较上期增加1.53%。2024年1月-9月，安科生物实现营业收入19.21亿元，同比减少4.95%；归母净利润5.90亿元，同比减少9.89%。
Why Moderna (MRNA) Stock Is Trading Higher
Moderna shares are trading higher by 3.1% Monday afternoon. The CDC reported a significant rise in acute respiratory ...
Moderna Inc. stock rises Monday, still underperforms market
Shares of Moderna Inc. MRNA inched 0.92% higher to $42.57 Monday, on what proved to be an all-around mixed trading session ...
来自MSN14 天
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?
Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...
bovnews4 天
Moderna Inc (MRNA) Stock: More Robust Than the Numbers Suggest?
Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $41.58 which represents a slight increase of $2.20 or 5.59% from the prior close of $39.38. The stock opened at $39.71 and touched a low ...
news.stocktradersdaily15 天
When (MRNA) Moves Investors should Listen
Check the time stamp on this data. Updated AI-Generated Signals for Moderna Inc. (MRNA) available here: MRNA.
bovnews7 天
Moderna Inc (MRNA) Stock Dilemma: A Drop That Has Everyone Talking—What’s the Real Story?
Moderna Inc (MRNA) stock saw a decline, ending the day at $40.13 which represents a decrease of $-0.30 or -0.74% from the prior close of $40.43. The stock opened at $40.35 and touched a low of $39.79 ...
和讯网17 天
百克生物：Ⅱ型单纯疱疹病毒mRNA疫苗临床试验获批
LVRNA101即Ⅱ型单纯疱疹病毒mRNA疫苗。截至目前，全球暂无相关疫苗产品成功开发上市 证券时报e公司讯，百克生物(688276)12月20日晚间公告，公司近日 ...